Xilio Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2024 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q3 2024 | 1 | -$0.25 | -$0.25 | -$0.25 |
| Q4 2024 | 2 | -$0.26 | -$0.17 | -$0.22 |
| Q1 2025 | 1 | -$0.14 | -$0.14 | -$0.14 |
| Q2 2025 | 1 | -$0.14 | -$0.14 | -$0.14 |
| Q3 2025 | 1 | -$0.16 | -$0.16 | -$0.16 |
| Q4 2025 | 1 | $0.01 | $0.01 | $0.01 |
Xilio Therapeutics, Inc. Earnings Date And Information
Xilio Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.22 earnings per share for the quarter, topping analysts' consensus estimates of $-0.25 by $0.03. The company had revenue of 2.26 M for the quarter and had revenue of 0 for the year. Xilio Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.78 diluted earnings per share) and currently has a price-to-earnings ratio of -0.9. Xilio Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Xilio Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.25 | -$0.22 | 0.03 | $3.30 M | $2.26 M |
| 08/08/2024 | Q2 2024 | -$0.23 | -$0.24 | -0.01 | $30.00 M | $2.36 M |
| 05/14/2024 | Q1 2024 | -$0.30 | -$0.62 | -0.32 | $0 | |
| 04/01/2024 | Q4 2023 | -$0.64 | $2.90 M | |||
| 11/09/2023 | Q3 2023 | -$0.76 | -$0.61 | 0.15 | $0 | |
| 11/09/2023 | Q2 2023 | -$0.76 | -$0.70 | 0.06 | $0 | |
| 11/09/2023 | Q1 2023 | -$0.76 | -$0.78 | -0.02 | $0 | |
| 11/09/2023 | Q4 2022 | -$0.76 | -$0.79 | -0.03 | $0 | |
| 11/09/2022 | Q3 2022 | -$0.89 | -$0.71 | 0.18 | $0 | |
| 08/09/2022 | Q2 2022 | -$0.78 | -$0.90 | -0.12 | $0 | |
| 05/12/2022 | Q1 2022 | -$1.00 | -$0.78 | 0.22 | $0 | |
| 03/01/2022 | Q4 2021 | -$0.94 | -$0.98 | -0.04 | $0 | |
| 12/02/2021 | Q3 2021 | -$1.60 | -$0.61 | 0.99 | $0 | |
| 06/30/2021 | Q2 2021 | -$0.87 | $0 | |||
| 03/31/2021 | Q1 2021 | -$0.63 | $0 | |||
| 12/30/2020 | Q4 2020 | -$0.78 | $0 | |||
| 09/29/2020 | Q3 2020 | -$0.56 | $0 | |||
| 06/29/2020 | Q2 2020 | -$28.00 | $0 | |||
| 03/30/2020 | Q1 2020 | -$19.85 | $0 |
Xilio Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Xilio Therapeutics, Inc.'s earnings date?
Xilio Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
Did Xilio Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Xilio Therapeutics, Inc. (:XLO) reported $-0.22 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.25 by $0.03.
-
How can I listen to Xilio Therapeutics, Inc.'s earnings conference call?
The conference call for Xilio Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Xilio Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Xilio Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Xilio Therapeutics, Inc. generate each year?
Xilio Therapeutics, Inc. (:XLO) has a recorded net income of $0. Xilio Therapeutics, Inc. has generated $-2.78 earnings per share over the last four quarters.
-
What is Xilio Therapeutics, Inc.'s price-to-earnings ratio?
Xilio Therapeutics, Inc. (:XLO) has a price-to-earnings ratio of -0.9 and price/earnings-to-growth ratio is -0.03.
